View Filing Data

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
Document and Entity Information - USD ($) $ in Millions	Dec. 31, 2017	Mar. 01, 2018	Jun. 30, 2017
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	FY
Trading Symbol	RCKT
Entity Registrant Name	ROCKET PHARMACEUTICALS, INC.
Entity Central Index Key	0001281895
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		39,402,023
Entity Public Float			$ 45.4

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 78,720	$ 29,798
Short-term investments	21,294	96,675
Prepaid expenses and other current assets	1,033	1,876
Total current assets	101,047	128,349
Property and equipment, net	563	1,130
Other assets	168	168
Total assets	101,778	129,647
Current liabilities:
Accounts payable	451	1,592
Accrued expenses and other current liabilities	2,373	4,246
Accrued interest	1,246	1,204
Total current liabilities	4,070	7,042
Other long-term liabilities	403	477
Total liabilities	54,014	56,479
Commitments and Contingencies (Note 9)
Stockholders’ equity:
Preferred Stock, $0.001 par value: 5,000,000 shares authorized and no shares issued or outstanding
Common stock, $0.01 par value: 120,000,000 shares authorized at December 31, 2017 and December 31, 2016; 6,805,686 shares and 6,746,579 shares issued and outstanding at December 31, 2017 and December 31, 2016, respectively	68	67
Additional paid-in capital	316,086	312,032
Accumulated deficit	(268,374)	(238,877)
Accumulated other comprehensive loss	(16)	(54)
Total stockholders’ equity	47,764	73,168
Total liabilities and stockholders’ equity	101,778	129,647
2021 Convertible Notes [Member]
Current liabilities:
2021 Convertible Notes, net of issuance costs	$ 49,541	$ 48,960

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2017	Dec. 31, 2016
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	120,000,000	120,000,000
Common stock, shares issued	6,805,686	6,746,579
Common stock, shares outstanding	6,805,686	6,746,579

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Operating expenses:
Research and development	$ (14,193)	$ (31,985)
General and administrative	(12,544)	(9,894)
Loss from operations	(26,737)	(41,879)
Interest expense	(3,579)	(1,418)
Interest income	819	443
Net loss	$ (29,497)	$ (42,854)
Net loss per share attributable to common stockholders—basic and diluted	$ (4.36)	$ (6.41)
Weighted-average number of shares outstanding—basic and diluted	6,765,451	6,683,794

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (29,497)	$ (42,854)
Other comprehensive loss:
Net unrealized gain (loss) on marketable securities	38	(43)
Total comprehensive loss	$ (29,459)	$ (42,897)

Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]
Beginning Balance at Dec. 31, 2015	$ 108,813	$ 66	$ 304,781	$ (196,023)	$ (11)
Beginning Balance, shares at Dec. 31, 2015		6,605,849
Stock-based compensation	2,909		2,909
Stock options exercised, value	191		191
Stock options exercised, shares		13,577
Common stock issued pursuant to employee stock purchase plan, value	155		155
Common stock issued pursuant to employee stock purchase plan, shares		6,481
Issuance of common stock, net of $403 in offering costs, value	3,997	$ 1	3,996
Issuance of common stock, net of $403 in offering costs, shares		120,672
Unrealized comprehensive gain (loss) on marketable securities	(43)				(43)
Net loss	(42,854)			(42,854)
Ending Balance at Dec. 31, 2016	73,168	$ 67	312,032	(238,877)	(54)
Ending Balance, shares at Dec. 31, 2016		6,746,579
Stock-based compensation	4,036		4,036
Common stock issued pursuant to employee stock purchase plan, value	35		35
Common stock issued pursuant to employee stock purchase plan, shares		5,971
Issuance of common stock pursuant to settlement of restricted stock units, value		$ 1	(1)
Issuance of common stock pursuant to settlement of restricted stock units, shares		56,406
Shares surrendered by employees to pay taxes related to settlement of restricted stock	(16)		(16)
Shares surrendered by employees to pay taxes related to settlement of restricted stock, shares		(3,270)
Unrealized comprehensive gain (loss) on marketable securities	38				38
Net loss	(29,497)			(29,497)
Ending Balance at Dec. 31, 2017	$ 47,764	$ 68	$ 316,086	$ (268,374)	$ (16)
Ending Balance, shares at Dec. 31, 2017		6,805,686

Consolidated Statements of Changes in Stockholders' Equity (Parenthetical) $ in Thousands	12 Months Ended
	Dec. 31, 2016 USD ($)
IPO
Issuance of common stock, offering costs	$ 403

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Cash flows from operating activities:
Net loss	$ (29,497)	$ (42,854)
Adjustments to reconcile net loss to cash used in operating activities:
Noncash interest expense	581	222
Noncash rent	(59)	(60)
Noncash asset impairment charge	437
Amortization of premium on marketable securities	217	225
Depreciation	200	169
Stock-based compensation	4,036	2,909
Changes in operating assets and liabilities:
Prepaid expenses and other assets	960	(948)
Accounts payable	(1,141)	(41)
Accrued expenses and other liabilities	(1,846)	3,112
Net cash used in operating activities	(26,112)	(37,266)
Cash flows from investing activities:
Purchases of short-term investments	(27,204)	(122,277)
Proceeds from the maturities of short-term investments	102,289	56,705
Purchase of property and equipment	(70)	(487)
Net cash provided by (used in) investing activities	75,015	(66,059)
Cash flows from financing activities:
Net proceeds from issuance of common stock		3,997
Payments made for taxes of employees who surrendered shares related to settlement of restricted stock	(16)
Net cash provided by financing activities:	19	53,081
Net change in cash and cash equivalents	48,922	(50,244)
Cash and cash equivalents, beginning of period	29,798	80,042
Cash and cash equivalents, end of period	78,720	29,798
Supplemental disclosure of cash flow information:
Cash paid for interest	2,957
Supplemental disclosure of noncash investing and financing activities:
Net unrealized gain (loss) on marketable securities	38	(43)
2021 Convertible Notes [Member]
Cash flows from financing activities:
Proceeds from issuance of 2021 Convertible Notes		52,000
Payments of 2021 Convertible Notes issuance costs		(3,262)
Stock Option Plans [Member]
Cash flows from financing activities:
Proceeds from the issuance of common stock		191
Employee Stock Purchase Plan [Member]
Cash flows from financing activities:
Proceeds from the issuance of common stock	$ 35	$ 155

Organization and Operations	12 Months Ended
Organization and Operations	Dec. 31, 2017
Accounting Policies [Abstract]
Organization and Operations	1. Organization and Operations On January 4, 2018, Rome Merger Sub (“Merger Sub”), a wholly owned subsidiary of Inotek Pharmaceuticals Corporation (“Inotek”), completed its merger with and into Rocket Pharmaceuticals, Ltd., a privately held, multi-platform biotechnology company focused on the development of first-in-class gene therapies for rare and devastating pediatric diseases (“Private Rocket”), with Private Rocket surviving as a wholly owned subsidiary of Inotek. This transaction is referred to as the “Reverse Merger.” The Reverse Merger was effected pursuant to an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”), dated as of September 12, 2017, by and among Inotek, Private Rocket and Rome Merger Sub. Immediately prior to the Reverse Merger, on January 4, 2018, Inotek effected a 1-for-4 reverse stock split on its issued and outstanding common stock. The accompanying consolidated financial statements and notes to the consolidated financial statements give retroactive effect to the reverse stock split for all periods presented. Upon the closing of the Reverse Merger, each outstanding share of Private Rocket’s common stock converted into approximately 76.185 shares of Inotek’s common stock. In addition, each outstanding option to purchase Private Rocket’s common stock prior to the effective time of the Reverse Merger was converted into an option to purchase Inotek’s common stock. No fractional shares of Inotek’s common stock were issued in connection with the Reverse Merger. Instead, Private Rocket’s stockholders received cash in lieu of any fractional shares of Rocket’s common stock such stockholders would have otherwise been entitled to receive in accordance with the Merger Agreement. Immediately following the Reverse Merger, the combined company changed its name from “Inotek Pharmaceuticals Corporation” to “Rocket Pharmaceuticals, Inc.” The combined company following the Reverse Merger may be referred to herein as “the combined company,” “Rocket,” or “the Company.” The accompanying consolidated financial statements do not give effect to the Reverse Merger. The financial statements have been labeled “Inotek Pharmaceuticals Corporation” for the purposes of this filing, which was the entity name in effect for the historical periods presented. The Reverse Merger will be accounted for as a reverse merger under the acquisition method of accounting. After reviewing the relative voting rights, the composition of the board of directors and the composition of senior management of the combined company after the Reverse Merger, it was determined that Private Rocket will be treated as the accounting acquirer and Inotek will be treated as the “acquired” company for financial reporting purposes under the acquisition method of accounting. See Note 12. Prior to the Reverse Merger, Inotek was a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, including glaucoma. After failing to meet the primary endpoints in its first pivotal Phase 3 trial of trabodenoson monotherapy (“MATrX-1”) and its Phase 2 trial of trabodenoson in a fixed-dose combination therapy with latanoprost (“FDC”), Inotek voluntarily discontinued its development of trabodenoson in 2017. Historically, Inotek devoted substantially all of its resources to research and development efforts relating to its product candidates, including conducting clinical trials, providing general and administrative support for these operations and protecting its intellectual property. Inotek did not have any products approved for sale and did not generate any revenue from product sales or other sources. From Inotek’s inception through December 31, 2017, it funded its operations primarily through the sales of equity and debt securities. In February 2015, Inotek completed an initial public offering (“IPO”) of its common stock and a concurrent offering of convertible senior notes, raising an aggregate of $55,398 in net proceeds. In August 2015, Inotek completed a follow-on offering of its common stock, raising an aggregate of $73,965 in net proceeds. In August 2016, Inotek completed a second offering of convertible senior notes, raising an aggregate of $48,738 in net proceeds. Inotek incurred net losses in each year since its inception. As of December 31, 2017, Inotek had an accumulated deficit of $268,374 and cash and cash equivalents and short-term investments aggregating $100,014.

Significant Accounting Policies

12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Significant Accounting Policies

2. Significant Accounting Policies

Basis of Presentation—The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The consolidated financial statements reflect the operations of Inotek and its wholly owned subsidiaries, Inotek Securities Corporation, Inotek Ltd and Rome Merger Sub. All significant intercompany balances and transactions have been eliminated in consolidation. Certain reclassifications have been made to prior year amounts to conform to the current year presentation.

Segment Reporting—Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. Inotek views its operations and manages its business in one operating segment.

Use of Estimates—The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from these estimates. Significant items subject to such estimates and assumptions include the valuation of stock options used for the calculation of stock-based compensation and the calculation of accruals related to research and clinical development.

Comprehensive loss—Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions, and other events and circumstances from non-owner sources, and currently consists of net loss and changes in unrealized gains and losses on short-term investments. Accumulated other comprehensive loss consists entirely of unrealized gains and losses from short-term investments as of December 31, 2017 and 2016.

Cash and Cash Equivalents—Cash and cash equivalents consist of bank deposits, certificates of deposit and money market accounts. Cash equivalents are carried at cost which approximates fair value due to their short-term nature and which Inotek believes do not have a material exposure to credit risk. Inotek considers all highly liquid investments with maturities of three months or less from the date of purchase to be cash equivalents.

Inotek maintains its cash and cash equivalent balances in the form of money market, savings or operating accounts with financial institutions that management believes are creditworthy. Inotek’s cash and cash equivalent accounts, at times, may exceed federally insured limits. Inotek has not experienced any losses in such accounts. Inotek believes it is not exposed to any significant credit risk on cash and cash equivalents.

Short-term investments—Short-term investments consist of investments in certificates of deposit, agency bonds and United States Treasury securities. Management determines the appropriate classification of these securities at the time they are acquired and evaluates the appropriateness of such classifications at each balance sheet date. Inotek classifies its short-term investments as available-for-sale pursuant to Financial Accounting Standards Board (“FASB”) Accounting Standard Codification (“ASC”) 320, Investments—Debt and Equity Securities. Short-term investments are recorded at fair value, with unrealized gains and losses included as a component of accumulated other comprehensive loss in stockholders’ equity and a component of total comprehensive loss in the consolidated statements of comprehensive loss, until realized. Realized gains and losses are included in investment income on a specific-identification basis. There were no realized gains or losses on short-term investments for the twelve months ended December 31, 2017 and 2016. There were $38 of net unrealized gains and $43 of net unrealized losses on short-term investments as of December 31, 2017 and 2016, respectively.

Inotek reviews short-term investments for other-than-temporary impairment whenever the fair value of a short-term investment is less than the amortized cost and evidence indicates that a short-term investment’s carrying amount is not recoverable within a reasonable period of time. Other-than-temporary impairments of investments are recognized in the statements of operations if Inotek has experienced a credit loss, has the intent to sell the short-term investment, or if it is more likely than not that Inotek will be required to sell the short-term investment before recovery of the amortized cost basis. Evidence considered in this assessment includes reasons for the impairment, compliance with Inotek’s investment policy, the severity and the duration of the impairment and changes in value subsequent to the end of the period.

Short-term investments at December 31, 2017 consist of the following:

	Cost Basis		Unrealized Gains		Unrealized Losses			Fair Value
	(in thousands)
Current:
Certificates of deposit	$	3,667	$	—	$	—		$	3,667
United States Treasury securities		17,643		—		(16	)		17,627
	$	21,310	$	—	$	(16	)	$	21,294

Short-term investments at December 31, 2016 consist of the following:

	Cost Basis		Unrealized Gains		Unrealized Losses			Fair Value
	(in thousands)
Current:
Certificates of deposit	$	22,046	$	—	$	—		$	22,046
Agency bonds		5,917		—		(4	)		5,913
United States Treasury securities		68,766		1		(51	)		68,716
	$	96,729	$	1	$	(55	)	$	96,675

At December 31, 2017 and 2016, all short-term investments held by Inotek had contractual maturities of less than one year. Inotek evaluated its securities for other-than-temporary impairment and determined that no such impairment existed at December 31, 2017 and 2016.

Property and Equipment—Property and equipment are stated at cost. Expenditures for repairs and maintenance are charged to expense as incurred. Upon retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is reflected in the consolidated statement of operations. Depreciation and amortization is provided using the straight-line method over the estimated useful lives of the assets, which are as follows:

Asset Classification		Estimated Useful Life
Computer hardware and software		3 - 5 years
Laboratory equipment		5 years
Office equipment		5 years
Leasehold improvements		Shorter of useful life or remaining life of lease

Impairment of Long-Lived Assets—Inotek assesses the recoverability of its long-lived assets, which include property and equipment, whenever significant events or changes in circumstances indicate impairment may have occurred. If indicators of impairment exist, projected future undiscounted cash flows associated with the asset are compared to its carrying amount to determine whether the asset’s value is recoverable. Any resulting impairment is recorded as a reduction in the carrying value of the related asset in excess of fair value and charged to operating results (See Note 3).

Debt Issuance Costs—Debt issuance costs at December 31, 2017 and 2016 consist of underwriting discounts and offering-related costs incurred by Inotek in connection with the closing of the 2021 Convertible Notes and are included as a direct deduction from the carrying amount of the 2021 Convertible Notes on Inotek’s consolidated balance sheets. Inotek amortizes debt issuance costs to interest expense over the life of the 2021 Convertible Notes using the effective interest method. (See Note 5). Amortization of debt issuance costs was $581 and $222 for the twelve months ended December 31, 2017 and 2016, respectively.

Research and Development Costs—Research and development costs are charged to expense as incurred and include, but are not limited to:

•

employee-related expenses including salaries, benefits, travel and stock-based compensation expense for research and development personnel;

•

expenses incurred under agreements with contract research organizations that conduct clinical and preclinical studies, contract manufacturing organizations and consultants;

•

costs associated with preclinical and development activities; and

•

costs associated with regulatory operations.

Costs for certain development activities, such as clinical studies, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, and information provided to Inotek by its vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the patterns of costs incurred, and are reflected in the financial statements as accrued expenses, or prepaid expenses and other current assets, if the related services have not been provided.

Stock-Based Compensation —Inotek measures the cost of employee services received in exchange for an award of equity instruments based on the fair value of the award on the grant date. That cost is recognized on a straight-line basis over the period during which the employee is required to provide service in exchange for the award. The fair value of options on the date of grant is calculated using the Black-Scholes option pricing model based on key assumptions such as stock price, expected volatility and expected term. Inotek’s estimates of these assumptions are primarily based on the trading price of Inotek’s stock, historical data, peer company data and judgment regarding future trends and factors. The fair value of restricted stock awards is based on the intrinsic value of such awards on the date of grant. Compensation cost for stock purchase rights under the employee stock purchase plan is measured and recognized on the date Inotek becomes obligated to issue shares of our common stock and is based on the difference between the fair value of Inotek’s common stock and the purchase price on such date.

Fair Value Measurements—Inotek is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. FASB ASC 820, Fair Value Measurements and Disclosures (“ASC 820”), establishes a hierarchy of inputs used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of Inotek. Unobservable inputs are inputs that reflect Inotek’s assumptions about the inputs that market participants would use in pricing the asset or liability, and are developed based on the best information available in the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The three levels of the fair value hierarchy are described below:

Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that Inotek has the ability to access at the measurement date.

Level 2—Valuations based on quoted prices for similar assets or liabilities in markets that are not active or for which all significant inputs are observable, either directly or indirectly.

Level 3—Valuations that require inputs that reflect Inotek’s own assumptions that are both significant to the fair value measurement and unobservable.

To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by Inotek in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

Inotek’s material financial instruments at December 31, 2017 and 2016, consisted of cash and cash equivalents, short-term investments, accounts payable and the 2021 Notes. The fair value of Inotek’s cash and cash equivalents and accounts payable approximate their respective carrying values due to the short-term nature of these instruments and amounts. Inotek estimates the fair value of the 2021 Notes using quoted market prices obtained from third-party pricing services, which is classified as a Level 2 input due to limited market trading. As of December 31, 2017 and 2016, the fair value of the 2021 Notes was approximately $38,610 and $55,640, respectively, which differed from the 2021 Notes’ carrying value at each such date. Inotek’s assets and liabilities measured at fair value on a recurring basis include its short-term investments. There were no material liability-classified warrants, derivatives or derivative liabilities outstanding in 2017 or 2016.

Income taxes—Inotek uses the asset and liability method for accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases. Deferred tax assets and liabilities are measured using enacted rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is recorded if it is more likely than not that a deferred tax asset will not be realized. Inotek has provided a full valuation allowance on its deferred tax assets.

Inotek recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority.

Inotek recognizes interest and penalties related to uncertain tax positions in income tax expense. As of December 31, 2017 and 2016, Inotek had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in Inotek’s statements of operations.

Net loss per share—Inotek calculates net loss per share in accordance with FASB ASC 260, Earnings per Share. Basic earnings (loss) per share (“EPS”) is calculated by dividing the net income or loss applicable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration of unissued common stock equivalents. The net loss applicable to common stockholders is determined by the reported net loss for the period and deducting dividends accrued and accretion of preferred stock. Diluted EPS is calculated by adjusting the weighted average common shares outstanding for the dilutive effect of common stock options, warrants, and convertible preferred stock and accrued but unpaid convertible preferred stock dividends. In periods where a net loss is recorded, no effect is given to potentially dilutive securities, as their effect would be anti-dilutive.

The following table sets forth the computation of basic and diluted EPS attributable to Inotek’s common stockholders:

	For the Years Ended December 31,
	2017			2016
	(in thousands, except share and per share amounts)
Numerator:
Net loss applicable to common stockholders	$	(29,497	)	$	(42,854	)
Denominator:
Weighted average common shares outstanding—basic and diluted		6,765,451			6,683,794
Net loss per share applicable to common stockholders—basic and diluted	$	(4.36	)	$	(6.41	)

The following common stock equivalents were excluded from the calculation of diluted net loss per share for the periods indicated as including them would have an anti-dilutive effect:

	For the Years Ended December 31,
	2017		2016
Shares issuable upon conversion of the 2021 Convertible Notes		1,620,947		1,620,947
Warrants for common stock		14,102		14,102
Stock options		523,520		668,864
Restricted Stock Units		271,719		117,500
Total		2,430,288		2,421,413

Subsequent Events—Inotek considers events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Inotek has completed an evaluation of all subsequent events through the date the financial statements were issued. See Note 12.

Recent Accounting Pronouncements—In May 2014, the FASB issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers. The standard, including subsequently issued amendments, will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective and permits the use of either the retrospective or cumulative effect transition method. The standard will require an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The standard will be effective for annual and interim periods beginning after December 15, 2017. Inotek does not currently generate revenue or have any arrangements that are subject to this guidance.

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which supersedes the current leasing guidance and upon adoption, will require lessees to recognize right-of-use assets and lease liabilities on the balance sheet for all leases with terms longer than 12 months. The new standard is effective for Inotek for the annual period beginning after December 15, 2018, and can be early adopted by applying a modified retrospective approach for leases existing at, and entered into after, the beginning of the earliest comparable period presented in the financial statements. Inotek is currently evaluating the impact of this accounting standard update on its consolidated financial statements.

In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting, which amends FASB ASC Topic 718, Compensation – Stock Compensation (“ASC 718”), and includes provisions intended to simplify various aspects related to how share-based payments are accounted for and presented in the financial statements. The new standard is effective for Inotek for the annual period beginning after December 15, 2016, and for annual and interim periods thereafter, with early adoption permitted. Inotek adopted this standard on January 1, 2017. The update revises requirements in the following areas: minimum statutory withholding, accounting for income taxes, and forfeitures. Prior to adoption, Inotek applied a 0% forfeiture rate to share-based compensation, resulting in no cumulative effect adjustment to the opening period. Upon adoption of ASU 2016-09, Inotek’s accounting policy is to recognize forfeitures as they occur. The update also requires Inotek to recognize the income tax effect of awards in the income statement when the awards vest or are settled. Finally, the update allows Inotek to repurchase more of an employee’s shares than it can today for tax withholding purposes without triggering a liability. The income tax related items had no effect on the current period presentation and Inotek maintains a full valuation allowance against its deferred tax assets.

In May 2017, the FASB issued ASU 2017-09, Scope of Modification Accounting, which clarifies the scope under which modification accounting should be applied to a share-based payment award under ASC 718. The standard will be effective for annual reporting periods and interim periods within those annual periods, beginning after December 15, 2017, and early adoption is permitted for interim or annual period beginning after January 1, 2017. Inotek is currently evaluating the impact of this accounting standard update on its consolidated financial statements.

Property and Equipment

12 Months Ended

Dec. 31, 2017

Property Plant And Equipment [Abstract]

Property and Equipment

3. Property and Equipment

At December 31, 2017 and 2016, Inotek’s property and equipment consisted of the following:

	December 31,
	2017			2016
	(in thousands)
Office equipment	$	357		$	407
Computer hardware and software		96			263
Laboratory equipment		—			446
Leasehold improvements		445			445
Total		898			1,561
Less: accumulated depreciation		(335	)		(431	)
Property and equipment, net	$	563		$	1,130

During the years ended December 31, 2017 and 2016, Inotek recognized $200 and $169 of depreciation expense, respectively, and wrote off $217 of fully depreciated net assets in the year ended December 31, 2017.

In 2017, Inotek voluntarily discontinued its development of trabodenoson and classified its equipment used in the production of trabodenoson as held for sale. Inotek performed an impairment assessment of this equipment by comparing the equipment’s carrying value to its estimated fair value, which was based on prices obtained for similar assets. The analysis resulted in an impairment of Inotek’s laboratory equipment of $437 which was charged to research and development expenses in 2017.

Accrued Expenses and Other Current Liabilities

12 Months Ended

Dec. 31, 2017

Payables And Accruals [Abstract]

Accrued Expenses and Other Current Liabilities

4. Accrued Expenses and Other Current Liabilities

At December 31, 2017 and 2016, Inotek’s accrued expenses and other current liabilities consisted of the following:

	December 31,
	2017		2016
	(in thousands)
Compensation and benefits	$	793	$	1,627
Professional fees		528		311
Government payable		506		478
Severance and benefits		270		544
Research and development		151		1,148
Other		125		138
Total	$	2,373	$	4,246

Debt

12 Months Ended

Dec. 31, 2017

Debt Disclosure [Abstract]

Debt

5. Debt

2021 Convertible Notes

On August 5, 2016, Inotek issued an aggregate of $50,000 of the 2021 Convertible Notes. On August 30, 2016, Inotek issued an additional $2,000 of 2021 Convertible Notes pursuant to the exercise of the underwriters’ overallotment option. The 2021 Convertible Notes have a maturity date of August 1, 2021 (“Maturity Date”), are unsecured and accrue interest at a rate of 5.75% per annum, payable semi-annually on February 1 and August 1 of each year, beginning February 1, 2017. In connection with the issuance of the 2021 Convertible Notes, the Company incurred $3,262 of debt issuance costs which were recorded as a discount on the 2021 Convertible Notes.

Each holder of a 2021 Convertible Note (the “Holder”) has the option until the close of business on the second business day immediately preceding the Maturity Date to convert all, or any portion, of the 2021 Convertible Notes held by it at a conversion rate of 31.1876 shares of Inotek’s common stock per $1 principal amount of 2021 Convertible Notes (the “Conversion Rate”). The Conversion Rate is subject to adjustment from time to time upon the occurrence of certain events, including the issuance of stock dividends and payment of cash dividends. In addition, in certain circumstances, the Conversion Rate will be increased in respect of a Holder’s conversion of 2021 Convertible Notes in connection with the occurrence of one or more corporate events specified in the indenture (as supplemented, the “Indenture”) governing the 2021 Convertible Notes (each such specified corporate event, a “Make-Whole Fundamental Change”) that occurs prior to the Maturity Date (a “Make-Whole Fundamental Change Conversion”) or in respect of a Holder’s voluntary conversion of 2021 Convertible Notes other than in connection with a Make-Whole Fundamental Change (a “Voluntary Conversion”). In connection with a Make-Whole Fundamental Change Conversion or a Voluntary Conversion, Inotek will increase the Conversion Rate for the 2021 Convertible Notes surrendered for conversion by a number of additional shares of Inotek’s common stock set forth in the Additional Shares Make-Whole Table in the Indenture, based on the applicable Stock Price (as defined in the Indenture) and Effective Date (as defined in the Indenture) for such conversion. The additional shares potentially issuable in connection with a Make-Whole Fundamental Change Conversion or a Voluntary Conversion range from 0 to 6.2375 per $1 principal amount of 2021 Convertible Notes, subject to adjustment. If the Stock Price applicable to any conversion is greater than $160.00 per share, the Conversion Rate will not be increased. If the Stock Price applicable to any conversion is less than $26.72 per share, the Conversion Rate in connection with a Make-Whole Fundamental Change Conversion will not be increased but it will be increased by 6.2375 shares in connection with a Voluntary Conversion. Upon conversion, Holders of the 2021 Convertible Notes will receive shares of Inotek’s common stock and cash in lieu of fractional shares.

Upon the occurrence of a Fundamental Change, the occurrence of certain change of control transactions or delisting events (as defined in the Indenture), each Holder may require Inotek to repurchase for cash all or any portion of the 2021 Convertible Notes held by such Holder at a repurchase price equal to 100% of the principal amount thereof, plus accrued and unpaid interest thereon.

Inotek, at its option, may redeem for cash all or any portion of the 2021 Convertible Notes if the last reported sale price of a share of Inotek’s common stock is equal to or greater than 200% of the conversion price for the 2021 Convertible Notes then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending within the five trading days immediately preceding the date on which Inotek provides notice of redemption, at a redemption price equal to 100% of the principal amount of the 2021 Convertible Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.

If an Event of Default (as defined in the Indenture), other than certain events of bankruptcy, insolvency or reorganization involving Inotek, occurs and is continuing, the trustee under the Indenture (the “Trustee”) or the Holders of at least 25% in principal amount of the outstanding 2021 Convertible Notes may declare 100% of the principal of and accrued and unpaid interest, if any, on all of the 2021 Convertible Notes to be due and payable immediately. Upon the occurrence of an Event of Default relating to bankruptcy, insolvency or reorganization involving Inotek, 100% of the principal of and accrued and unpaid interest, if any, on all of the 2021 Convertible Notes would become due and payable automatically.

Notwithstanding the foregoing, the Indenture provides that, to the extent Inotek elects, the sole remedy for an Event of Default relating to certain failures by Inotek to comply with certain reporting covenants in the Indenture, will (i) for the first 90 days after the occurrence of such an Event of Default, consist exclusively of the right to receive additional interest on the 2021 Convertible Notes at a rate equal to 0.25% per annum of the principal amount of the 2021 Convertible Notes outstanding for each day during such 90-day period on which such an Event of Default is continuing and (ii) for the period from, and including, the 91st day after the occurrence of such an Event of Default to, and including, the 180th day after the occurrence of such an Event of Default, consist exclusively of the right to receive additional interest on the 2021 Convertible Notes at a rate equal to 0.50% per annum of the principal amount of the 2021 Convertible Notes outstanding for each day during such additional 90-day period on which such an Event of Default is continuing (such additional interest, “Additional Interest”). After 180 days, if such Event of Default is not cured or waived, the 2021 Convertible Notes would be subject to acceleration in accordance with the Indenture.

The 2021 Convertible Notes are considered a hybrid financial instrument consisting of a fixed interest rate “host” and various embedded features that required evaluation as potential embedded derivatives under FASB ASC 815, Derivatives and Hedging (“ASC 815”). Based on the nature of the host instrument and the embedded features, management concluded that none of the conversion, put and redemption features required bifurcation and separate accounting from the host instrument. Inotek determined that the Additional Interest was an embedded derivative that contains non-credit related events of default. As a result, the Additional Interest feature required bifurcation and separate accounting under ASC 815. Based on the amount of Additional Interest that would be owed and the likelihood of occurrence, Inotek estimated the fair value of the Additional Interest feature to be insignificant upon issuance and as of December 31, 2017 and 2016.

The issuance costs which were recorded as a discount on the debt are being amortized to interest expense over the life of the 2021 Convertible Notes using the effective interest method. As of December 31, 2017, the stated interest rate was 5.75%, and the effective interest rate was 7.3%. For the year ended December 31, 2017, interest expense related to the 2021 Convertible Notes, was $3,579, including $581 related to amortization of the debt discount. For the year ended December 31, 2016, interest expense related to the 2021 Convertible Notes, was $1,418, including $222 related to amortization of the debt discount.

The table below summarizes the carrying value of the 2021 Convertible Notes as of December 31, 2017 and 2016:

	(in thousands)
Gross proceeds	$	52,000
Initial value of issuance costs recorded as debt discount		(3,262	)
Amortization of debt discount		222
Carrying value as of December 31, 2016		48,960
Amortization of debt discount		581
Carrying value as of December 31, 2017	$	49,541

Income Taxes

12 Months Ended

Dec. 31, 2017

Income Tax Disclosure [Abstract]

Income Taxes

6. Income Taxes

No provision for federal or state income taxes was recorded during the years ended December 31, 2017 and 2016, as Inotek incurred operating losses for each of these years.

Net loss by jurisdiction consists of the following:

	For the Years Ended December 31,
	2017		2016
	(in thousands)
Domestic	$	28,281	$	41,821
Foreign		1,216		1,033
Total	$	29,497	$	42,854

A reconciliation between the effective tax rates and statutory rates for the years ended December 31, 2017 and 2016 is as follows:

	For the Years Ended December 31,
	2017				2016
Computed at statutory rate		34.00		%		34.00		%
State income taxes		4.34				4.76
Tax credits		1.76				3.38
Other		(6.04	)			(1.74	)
Federal rate change		(79.56	)			—
Valuation allowance		45.50				(40.40	)
		—		%		—		%

The tax effect of significant temporary differences representing deferred tax assets and liabilities as of December 31, 2017 and 2016 is as follows:

	December 31,
	2017			2016
	(in thousands)
Net operating loss (“NOL”) and credit carryforwards	$	37,252		$	43,765
Capitalized research and development costs		16,115			22,775
Other		1,722			1,963
Valuation allowance		(55,089	)		(68,503	)
	$	—		$	—

On December 22, 2017, the Tax Cuts and Jobs Act (“TCJA”) was enacted and significantly revised the U.S. income tax law. The TCJA includes changes which reduce the corporate income tax rate from 35% to 21% for years beginning after December 31, 2017, and establish a territorial-style system for taxing foreign-source income of domestic multinational companies.

GAAP requires re-measurement of US deferred tax assets and liabilities to reflect the impact of a tax rate reduction in the period that includes enactment date. As a result, Inotek has revalued its deferred taxes assets and liabilities to 21% in the December 31, 2017 financial statements and the impact was offset by Inotek’s valuation allowance. Inotek has reflected the associated impact in the reconciliation of its effective tax rate above.

On December 22, 2017, Staff Accounting Bulletin No. 118 (“SAB 118”) was issued and allows a company to recognize provisional amounts when it does not have the necessary information available, prepared or analyzed, including computations, in reasonable detail to complete its accounting for the change in tax law. SAB 118 provides for a measurement of up to one year from the date of enactment. Inotek has not yet fully completed its analysis of the TCJA, however based on the total unrepatriated accumulated foreign earnings, Inotek does not believe any additional income taxes are due as any income, if determined, will be fully offset by Inotek’s NOL carryforwards.

As required by ASC 740, Income Taxes, management of Inotek has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets, which are comprised principally of NOL carryforwards and capitalized research and development costs. As a result of the fact that Inotek has incurred tax losses from inception, management has determined that it is more likely than not that Inotek will not recognize the benefits of federal and state net deferred tax assets and, as a result, a full valuation allowance has been established against its net deferred tax assets as of December 31, 2017 and 2016. Inotek has offset certain deferred tax liabilities with deferred tax assets that are expected to generate offsetting deductions within the same period. During the years ended December 31, 2017 and 2016, the valuation allowance decreased by $13,414 and increased by $17,312, respectively. Realization of deferred tax assets is dependent upon the generation of future taxable income.

As of December 31, 2017, Inotek had federal NOL carryforwards for income tax purposes of $127,132 that expire at various dates through 2037, and state NOL carryforwards of $83,428 that expire at various dates through 2037, available to reduce future federal and state income taxes, if any. As of December 31, 2017, Inotek had federal research and development tax credits of $5,171, and state research and development tax credits of $819. If substantial changes in Inotek’s ownership should occur, as defined in Section 382 of the Internal Revenue Code of 1986, as amended, (the “Code”), there could be annual limitations on the amount of loss carryforwards which can be realized in future periods. Inotek has determined that it has experienced prior ownership changes occurring in 2005, 2007 and 2015. The pre-change NOL carryforwards, although subject to an annual limitation, as well as any post-change NOL carryforwards, can be utilized in future years, provided that sufficient income is generated and no future ownership changes occur that may limit Inotek’s NOL carryforwards.

As of December 31, 2017 and 2016, Inotek’s total unrecognized tax benefits totaled $535 and $488, respectively, which if recognized would affect the effective tax rate prior to the adjustment for Inotek’s valuation allowance. Inotek files income tax returns in the U.S. federal and Massachusetts tax jurisdictions. Starting in tax year 2016, Inotek filed tax returns in the New Jersey tax jurisdiction. Tax years 2014 through 2017 remain open to examination by the tax jurisdictions in which Inotek is subject to tax. Since Inotek is in a loss carryforward position, the Internal Revenue Service (“IRS”) and state taxing authorities are permitted to audit the earlier tax years and propose adjustments up to the amount of the NOL carryforwards generated. Inotek is not currently under examination by the IRS or any other jurisdiction for any tax years.

The change in unrecognized tax benefits for each of the years ended December 31, 2017 and 2016 is as follows:

	For the Years Ended December 31,
	2017			2016
	(in thousands)
Balance at January 1,	$	488		$	333
Additions for prior year tax positions		(4	)		6
Additions for current year tax positions		51			149
	$	535		$	488

The Reverse Merger is expected to result in a substantial reduction to Inotek’s NOL carryforwards and unrecognized tax benefits.

Equity	12 Months Ended
Equity	Dec. 31, 2017
Equity [Abstract]
Equity	7. Equity Authorized Shares As of December 31, 2017, Inotek’s authorized capital stock consisted of 120,000,000 shares of common stock, par value $0.01 per share, and 5,000,000 shares of undesignated preferred stock, par value $0.001 per share. Reverse Stock Split On January 4, 2018, in connection with the Reverse Merger, Inotek effected a 1-for-4 reverse stock split on its issued and outstanding common stock. Inotek’s historical share and per share information has been retroactively adjusted in the financial statements presented to give effect to this reverse stock split. Common Stock All preferences, voting powers, relative, participating, optional, or other specific rights and privileges, limitations, or restrictions of the common stock are expressly subject to those that may be fixed with respect to any shares of preferred stock. Common stockholders are entitled to one vote per share, and to receive dividends, when and if declared by the Board. There were 6,805,686 and 6,746,579 shares of common stock outstanding at December 31, 2017 and 2016, respectively. Preferred Stock As of December 31, 2017 and 2016, there were no shares of preferred stock issued and outstanding.

Stock Plans

12 Months Ended

Dec. 31, 2017

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock Plans

8. Stock Plans

Inotek maintains three equity compensation plans: the Amended and Restated 2014 Stock Option and Incentive Plan (the “2014 Plan”), the 2004 Stock Option and Incentive Plan (the “2004 Plan”), and the 2014 Employee Stock Purchase Plan (“ESPP”).

Amended and Restated 2014 Stock Option and Incentive Plan

In August 2014, Inotek’s board of directors adopted the 2014 Plan for the issuance of incentive and non-qualified stock options, restricted stock, and other equity awards, all for common stock, as determined by the board of directors to employees, officers, directors, consultants, and advisors of Inotek and its subsidiaries. Pursuant to the provisions of the 2014 Plan and approval by the board of directors, on January 1, 2018 an additional 272,227 shares were added to the 2014 Plan representing 4% of total common shares issued and outstanding at December 31, 2017. There were 207,579 shares available for issuance under the 2014 Plan as of December 31, 2017. The 2014 Plan expires in August 2024.

In December 2016, the board granted to certain executive officers an aggregate of 117,500 restricted stock units (“RSUs”) pursuant to the 2014 Plan. Each restricted stock unit represents a contingent right to receive one share of Inotek’s common stock. Vesting for these RSUs was based equally on the achievement of two performance-based conditions, subject to continued service through such achievement dates. The intrinsic fair value of these RSUs as of the date of grant was $3,055 and no stock-based compensation expense was recorded in 2016 as Inotek determined that the vesting conditions were not probable of occurring. In January 2017, these RSUs were modified such that instead of vesting based on the achievement of certain performance-based conditions, they would vest in equal annual installments over four years from the December 2016 date of grant, subject to continued service through such dates. This change in vesting criteria was accounted for as a modification under ASC 718 whereby Inotek is recognizing the $717 fair value of the grants as of the date of modification over the vesting term.

In September 2017, Inotek accelerated the vesting of all unvested RSUs and stock options held by the ten terminated employees and recorded an incremental charge related to these modifications of $158, of which $142 and $16 was reflected in research and development and general and administrative expenses, respectively. Inotek also modified the employment agreements with certain of its remaining employees such that in the event of a change in control, if the employee experiences a qualifying termination by Inotek any time prior to or within 12 months of the change in control, all such employee’s outstanding stock options and RSUs will vest in full and the stock options will become exercisable. Inotek determined that the original awards were expected to vest under their original terms both prior to and after the modification. A comparison of the fair value of the outstanding stock awards immediately before and after the modification resulted in no incremental expense.

In October 2017, Inotek extended the exercise period for stock options held by each of its then remaining employees and directors. This change in expected term criteria was accounted for as a modification under ASC 718 whereby Inotek recorded an incremental charge of $856, of which $196 and $660 was reflected in research and development and general and administrative expenses, respectively.

The following table summarizes the option activity for each of the years ended December 31, 2017 and 2016 under the 2014 Plan:

	Number of Shares			Weighted- Average Exercise Price Per Share		Aggregate Intrinsic Value
						(in thousands)
Outstanding as of December 31, 2015		405,190		$	19.80
Granted		289,125		$	31.08
Exercised		(21,107	)	$	18.84
Cancelled		(7,000	)	$	27.16
Outstanding as of December 31, 2016		666,208		$	24.64	$	2,064
Granted		78,750		$	7.20
Exercised		—
Cancelled		(223,062	)	$	27.04
Outstanding as of December 31, 2017		521,896		$	20.96	$	255
Vested and exercisable as of December 31, 2017		335,230		$	20.36	$	128
Weighted-average years remaining on contractual life		7.80
Unrecognized compensation cost related to non-vested stock options	$	3,459

The weighted-average fair value of all stock options granted for the years ending December 31, 2017 and 2016 was $5.72 and $20.92, respectively. Intrinsic value at December 31, 2017 and 2016 is based on the closing price of Inotek’s common stock of $10.44 and $24.40 per share, respectively. As of December 31, 2017, all options granted are expected to vest.

In 2016, 7,530 shares of the 21,107 total options exercised were surrendered to Inotek pursuant to a net exercise right.

Unrecognized compensation cost related to non-vested stock options at December 31, 2017 includes $462 related to the October 2017 modification to extend the exercise period for certain unvested stock options.

The following table summarizes the RSU activity for each of the years ended December 31, 2017 and 2016 under the 2014 Plan:

	Number of Shares			Weighted- Average Grant Date Fair Value Per Share
Outstanding as of December 31, 2015		-
Granted		117,500		$	26.00
Vested		-
Cancelled		-
Outstanding as of December 31, 2016		117,500		$	26.00
Granted		232,750		$	6.40
Vested and settled		(56,406	)	$	6.76
Cancelled		(22,125	)	$	6.80
Outstanding as of December 31, 2017		271,719		$	4.20

As noted above, all outstanding RSUs were modified in the year ended December 31, 2017. Therefore, the weighted average grant date fair value per share of outstanding RSUs as of December 31, 2017, reflects the $4.20 per share fair value of the outstanding RSUs as of the date of modification.

Shares issued for RSUs that vested and settled in the year ended December 31, 2017, included 3,270 shares of common stock surrendered by employees for payment of $16 of withholding taxes due, resulting in a net issuance of 53,136 shares. Also, there were 29,375 RSUs that vested but remained unsettled as of December 31, 2017, per the terms of the Restricted Stock Unit Agreements. These RSUs are expected to settle no later than March 15, 2018.

2004 Stock Option and Incentive Plan

In July 2004, Inotek’s board of directors adopted the 2004 Plan for the issuance of incentive stock options, restricted stock, and other equity awards, all for common stock, as determined by the board of directors to employees, officers, directors, consultants, and advisors of Inotek and its subsidiaries. Only stock options were granted under the 2004 Plan. The 2004 Plan expired in February 2014 but remains effective for all outstanding options.

The following table summarizes stock option activity for each of the years ended December 31, 2017 and 2016 under the 2004 Plan:

	Number of Shares			Weighted- Average Exercise Price Per Share		Aggregate Intrinsic Value
						(in thousands)
Outstanding as of December 31, 2015		2,729		$	162.32
Exercised		—		$	—
Expired		—		$	—
Cancelled		(73	)	$	162.32
Outstanding as of December 31, 2016		2,656		$	162.32
Exercised		—		$	—
Expired		(570	)	$	162.32
Cancelled		(462	)	$	162.32
Outstanding as of December 31, 2017		1,624		$	162.32	$	—
Vested and exercisable as of December 31, 2017		1,624		$	162.32	$	—
Weighted-average years remaining on contractual life		0.66
Unrecognized compensation cost related to non-vested stock options	$	—

Inotek recorded no stock compensation expense in the years ended December 31, 2017 and 2016 relating to stock options granted pursuant to the 2004 Plan. At December 31, 2017, all 2004 Plan options were fully vested and there was no unrecognized stock-based compensation expense relating to stock options granted pursuant to the 2004 Plan. Options outstanding as of December 31, 2017 had no intrinsic value, as the option price exceeded the fair value of the underlying shares.

Employee Stock Purchase Plan

In November 2014, Inotek’s board of directors adopted and the stockholders approved the ESPP. The ESPP provides that the number of shares reserved and available for issuance under the ESPP shall be cumulatively increased each January 1, beginning on January 1, 2016, by the lesser of (i) 600,000 shares of common stock or (ii) the number of shares necessary to set the number of shares of common stock under the ESPP at 1% percent of the outstanding number of shares as of January 1 of the applicable year. However, the board of directors reserves the right to determine that there will be no increase for any year or that any increase will be for a lesser number of shares. As of January 1, 2018, 6,562 shares were added to the ESPP. As of December 31, 2017, there were 61,494 shares available for issuance under the ESPP.

All employees who are whose customary employment is for more than 20 hours a week are eligible to participate in the ESPP. Any employee who owns 5% or more of the voting power or value of Inotek’s shares of common stock is not eligible to purchase shares under the ESPP. Each employee who is a participant in the ESPP may purchase shares by authorizing payroll deductions of up to 10% of his or her base compensation during an offering period. Unless the participating employee has previously withdrawn from the offering, his or her accumulated payroll deductions will be used to purchase shares of common stock on the last business day of the offering period at a price equal to 85% of the fair market value of the ordinary shares on the first business day or the last business day of the offering period, whichever is lower, provided that no more than 5,000 shares of common stock may be purchased by any one employee during each offering period. Under applicable tax rules, an employee may purchase no more than $25,000 worth of stock, valued at the start of the purchase period, under the ESPP in any calendar year.

In 2017, 5,971 shares of common stock were purchased pursuant to the ESPP, resulting in proceeds to Inotek of $35. Inotek recorded $6 of stock-based compensation expense pursuant to the ESPP during the year ended December 31, 2017. In 2016, $155 was withheld and used to purchase 6,481 shares of common stock and Inotek recorded $66 of stock-based compensation expense pursuant to the ESPP.

Stock-Based Compensation

Stock-based compensation expense for options, RSUs and the ESPP is reflected in the consolidated statements of operations as follows:

	December 31,
	2017		2016
	(in thousands)
Research and development	$	1,287	$	1,362
General and administrative		2,749		1,547
Total	$	4,036	$	2,909

Commitments and Contingencies

12 Months Ended

Dec. 31, 2017

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

9. Commitments and Contingencies

Operating Leases

In 2015, Inotek entered into a lease agreement (the “Office Lease”) for its headquarters in Lexington, Massachusetts. Inotek occupied this space in September 2015, at which time its rental obligations commenced. Inotek recorded $445 as leasehold improvements for costs incurred to build out the space, and is amortizing those costs to facilities expense over the term of the lease. Rent expense is recognized on a straight-line basis at the average monthly rent over the term of the lease. Deferred rent is included in other current and long-term liabilities on Inotek’s consolidated balance sheets.

In 2016, Inotek signed an amendment to the Office Lease, whereby it agreed to rent additional space (the “Lease Amendment”). Inotek occupied the additional space on July 1, 2016. The terms of the Lease Amendment follow the terms of the Office Lease. The lease term is 90 months and Inotek has the right to extend the term for one period of five years.

Rent expense was $337 and $275 for the years ended December 31, 2017 and 2016, respectively. As of December 31, 2017, the remaining aggregate annual commitments pursuant to the Office Lease and the Lease Amendment are as follows:

Year	(in thousands)
2018	$	411
2019		421
2020		430
2021		439
2022		445
Thereafter		74
Total	$	2,220

Employee Agreements

In September 2017, Inotek modified the employment agreements with certain of its remaining employees such that in the event of termination in connection with a change in control (“CIC”), Inotek will provide these employees severance payments at each employee’s current monthly salary rate, and continued medical, dental and vision coverage pursuant to COBRA (of the employer’s portion of the premium cost) for up to six months primarily depending on duration of each individual employee’s service. Inotek also modified the employment agreements with certain of its named executive officers. In the event of a qualifying termination in connection with a CIC, for each of Inotek’s Chief Medical Officer and Vice President, Finance, Inotek will pay (i) twelve and six months’ severance, respectively, at each person’s current monthly salary rate, and (ii) continued medical, dental and vision coverage pursuant to COBRA (of the employer’s portion of the premium cost), for twelve and six months, respectively. In the event of a qualifying termination in connection with a CIC, in addition to the severance benefits previously provided to Inotek’s Chief Executive Officer (consisting of a lump-sum payment equal to 18 months’ base salary), Inotek agreed to provide continued medical, dental and vision coverage pursuant to COBRA (of the employer’s portion of the premium cost), for eighteen months. In addition, Inotek committed to paying to all seven remaining employees, if they were employees on the date of a CIC, a retention bonus, with the aggregate of all such retention bonuses equal to approximately $642.

Also, upon a CIC, Inotek would owe Perella Weinberg a fee of $2,000.

All payments described above became due and payable upon the consummation of the Reverse Merger in January 2018.

Securities Litigation

On January 6, 2017, a purported stockholder of Inotek filed a putative class action in the U.S. District Court for the District of Massachusetts, captioned Whitehead v. Inotek Pharmaceuticals Corporation, et al., No. 1:17-cv-10025. An amended complaint was filed on July 10, 2017, and a second amended complaint was filed on September 5, 2017. The second amended complaint alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5 against the Company, David Southwell, and Rudolf Baumgartner based on allegedly false and misleading statements and omissions regarding Inotek’s phase 2 and phase 3 clinical trials of trabodenoson. The lawsuit seeks, among other things, unspecified compensatory damages for purchasers of Inotek’s common stock between July 23, 2015 and July 10, 2017, as well as interest and attorneys’ fees and costs. The defendants filed a motion to dismiss the second amended complaint on October 6, 2017, the plaintiffs opposed the motion on December 5, 2017, and the defendants filed a reply on January 16, 2018. Inotek continues to vigorously defend itself against this claim.

From time to time, Inotek may be subject to other various legal proceedings and claims that arise in the ordinary course of its business activities. Although the results of litigation and claims cannot be predicted with certainty, Inotek does not believe it is party to any other claim or litigation the outcome of which, if determined adversely to Inotek, would individually or in the aggregate be reasonably expected to have a material adverse effect on its business. Regardless of the outcome, litigation can have an adverse impact on Inotek because of defense and settlement costs, diversion of management resources and other factors.

Termination of Chief Scientific Officer

In October 2016, Inotek entered into a Transition Agreement with its former Chief Scientific Officer, William K. McVicar, Ph.D. (the “Transition Agreement”). Pursuant to the terms of the Transition Agreement, Dr. McVicar remained an employee of the Company as a Senior Advisor for a six-month period ending April 4, 2017 (the “Transition Period”) and for twelve months thereafter will receive his salary and medical benefits at the same rate in effect as of the date of the Transition Agreement. Inotek recorded a charge in research and development expense of approximately $862 in 2016 related to the Transition Agreement, including approximately $215 related to stock options expected to vest during the Transition Period. Through December 31, 2017, Inotek has made payments of approximately $591 to Dr. McVicar, including $102 related to his 2016 bonus payment which was accrued prior to his termination. As of December 31, 2017, Inotek had $106 in accrued severance related to Dr. McVicar.

Indemnification Arrangements

As permitted under Delaware law, Inotek’s bylaws provide that Inotek will indemnify any director, officer, employee or agent of Inotek or anyone serving in these capacities. The maximum potential amount of future payments Inotek could be required to pay is unlimited. Inotek has insurance that reduces its monetary exposure and would enable it to recover a portion of any future amounts paid. As a result, Inotek believes that the estimated fair value of these indemnification commitments is minimal.

Throughout the normal course of business, Inotek has agreements with vendors that provide goods and services required by Inotek to run its business. In some instances, vendor agreements include language that requires Inotek to indemnify the vendor from certain damages caused by Inotek’s use of the vendor’s goods and/or services. Inotek has insurance that would allow it to recover a portion of any future amounts that could arise from these indemnifications. As a result, Inotek believes that the estimated fair value of these indemnification commitments is minimal.

Fair Value of Financial Measurements

12 Months Ended

Dec. 31, 2017

Fair Value Disclosures [Abstract]

Fair Value of Financial Measurements

10. Fair Value of Financial Measurements

Items measured at fair value on a recurring basis are short term investments. The following table sets forth Inotek’s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy:

	Fair Value Measurements at
	December 31, 2017
	Total		Level 1		Level 2		Level 3
	(in thousands)
Assets:
Money market mutual funds (included in cash and cash equivalents)	$	76,949	$	76,949	$	—	$	—

Certificates of deposit	$	3,667	$	—	$	3,667	$	—
United States Treasury securities		17,627		17,627		—		—
Short-term investments	$	21,294	$	17,627	$	3,667	$	—

	Fair Value Measurements at
	December 31, 2016
	Total		Level 1		Level 2		Level 3
	(in thousands)
Assets:
Money market mutual funds (included in cash and cash equivalents)	$	20,698	$	20,698	$	—	$	—

Certificates of deposit	$	22,046	$	—	$	22,046	$	—
Agency bonds		5,913		—		5,913		—
United States Treasury securities		68,716		68,716		—		—
Short-term investments	$	96,675	$	68,716	$	27,959	$	—

Money market mutual funds

Inotek classifies its money market mutual funds as Level 1 assets under the fair value hierarchy as these assets have been valued using quoted market prices in active markets without any valuation adjustment.

Short-term investments

Inotek classifies its United States Treasury securities as Level 1 assets under the fair value hierarchy as these assets have been valued using quoted market prices in active markets without any valuation adjustment. Inotek classifies its certificates of deposit as Level 2 assets under the fair value hierarchy, as there are no quoted market prices in active markets, and its agency bonds as Level 2 assets under the fair value hierarchy, as these assets are not always valued daily using quoted market prices in active markets.

Benefit Plans	12 Months Ended
Benefit Plans	Dec. 31, 2017
Compensation Related Costs [Abstract]
Benefit Plans	11. Benefit Plans Retirement Plan Inotek sponsors a 401(k) savings plan (the “Savings Plan”) for all eligible U.S. employees. Inotek reserves the right to modify, amend, or terminate the Savings Plan. Employees may contribute up to the maximum allowed by the IRS, while Inotek contributes to the plan at the discretion of the board of directors. Inotek’s contributions to the plan for the years ended December 31, 2017 and 2016 were $154 and $168, respectively. On January 3, 2018, the Savings Plan was terminated.

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	12. Subsequent Events Completion of the Reverse Merger On January 4, 2018, Inotek completed the Reverse Merger with Private Rocket merging with Merger Sub. The Reverse Merger was effected pursuant to the Merger Agreement. Private Rocket is a multi-platform biotechnology company focused on the development of first-in-class gene therapies for rare and devastating pediatric diseases. The Reverse Merger will be accounted for as a reverse merger under the acquisition method of accounting. Under the acquisition method of accounting, Private Rocket will be treated as the accounting acquirer and Inotek will be treated as the “acquired” company for financial reporting purposes because, immediately upon completion of the Reverse Merger, Private Rocket stockholders held a majority of the voting interest of the combined company. Immediately prior to the Reverse Merger, on January 4, 2018, Inotek effected a 1-for-4 reverse stock split on its issued and outstanding common stock. Pursuant to the terms of the Merger Agreement, each outstanding share of Private Rocket common stock converted into approximately 76.185 shares of Inotek’s common stock (the “Exchange Ratio”). As a result of the reverse stock split, the per share exercise price of, and the number of shares of common stock underlying, Inotek’s stock options and warrants outstanding prior to the reverse stock split were automatically proportionally adjusted based on the 4-to-1 reverse stock split ratio in accordance with the terms of such options and warrants. The reverse stock split did not alter the par value of Inotek’s common stock or modify any voting rights or other terms of the common stock. Also in connection with the completion of the Reverse Merger, Inotek changed its name from “Inotek Pharmaceuticals Corporation” to “Rocket Pharmaceuticals, Inc.” Offering of Common Stock On January 24, 2018, Rocket entered into an underwriting agreement (the “Underwriting Agreement”) with Cowen and Company, LLC and Evercore Group L.L.C., as representatives (the “Representatives”) of the several underwriters (collectively with the Representatives, the “Underwriters”), pursuant to which the Company agreed to issue and sell up to 6,325,000 shares of common stock (the “Shares”), which includes 825,000 shares that were sold pursuant to an option granted to the Underwriters (the “Offering”). The Shares were offered and sold in the Offering at a public offering price of $13.25 per share and were purchased by the Underwriters from Rocket at a price of $12.455 per share. On January 26, 2018, Rocket received net proceeds from the Offering of $78,778, after deducting underwriting discounts and commissions. All the shares in the offering were sold by Rocket.

Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Basis of Presentation

Segment Reporting

Use of Estimates

Comprehensive loss

Cash and Cash Equivalents

Short-term investments

Short-term investments at December 31, 2017 consist of the following:

	Cost Basis		Unrealized Gains		Unrealized Losses			Fair Value
	(in thousands)
Current:
Certificates of deposit	$	3,667	$	—	$	—		$	3,667
United States Treasury securities		17,643		—		(16	)		17,627
	$	21,310	$	—	$	(16	)	$	21,294

Short-term investments at December 31, 2016 consist of the following:

	Cost Basis		Unrealized Gains		Unrealized Losses			Fair Value
	(in thousands)
Current:
Certificates of deposit	$	22,046	$	—	$	—		$	22,046
Agency bonds		5,917		—		(4	)		5,913
United States Treasury securities		68,766		1		(51	)		68,716
	$	96,729	$	1	$	(55	)	$	96,675

Property and Equipment

Asset Classification		Estimated Useful Life
Computer hardware and software		3 - 5 years
Laboratory equipment		5 years
Office equipment		5 years
Leasehold improvements		Shorter of useful life or remaining life of lease

Impairment of Long-Lived Assets

Debt Issuance Costs

Research and Development Costs

Research and Development Costs—Research and development costs are charged to expense as incurred and include, but are not limited to:

•

employee-related expenses including salaries, benefits, travel and stock-based compensation expense for research and development personnel;

•

expenses incurred under agreements with contract research organizations that conduct clinical and preclinical studies, contract manufacturing organizations and consultants;

•

costs associated with preclinical and development activities; and

•

costs associated with regulatory operations.

Stock-Based Compensation

Fair Value Measurements

Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that Inotek has the ability to access at the measurement date.

Level 2—Valuations based on quoted prices for similar assets or liabilities in markets that are not active or for which all significant inputs are observable, either directly or indirectly.

Level 3—Valuations that require inputs that reflect Inotek’s own assumptions that are both significant to the fair value measurement and unobservable.

Income taxes

Net loss per share

The following table sets forth the computation of basic and diluted EPS attributable to Inotek’s common stockholders:

	For the Years Ended December 31,
	2017			2016
	(in thousands, except share and per share amounts)
Numerator:
Net loss applicable to common stockholders	$	(29,497	)	$	(42,854	)
Denominator:
Weighted average common shares outstanding—basic and diluted		6,765,451			6,683,794
Net loss per share applicable to common stockholders—basic and diluted	$	(4.36	)	$	(6.41	)

The following common stock equivalents were excluded from the calculation of diluted net loss per share for the periods indicated as including them would have an anti-dilutive effect:

	For the Years Ended December 31,
	2017		2016
Shares issuable upon conversion of the 2021 Convertible Notes		1,620,947		1,620,947
Warrants for common stock		14,102		14,102
Stock options		523,520		668,864
Restricted Stock Units		271,719		117,500
Total		2,430,288		2,421,413

Subsequent Events

Recent Accounting Pronouncements

Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Schedule of Short-term Investment

Short-term investments at December 31, 2017 consist of the following:

	Cost Basis		Unrealized Gains		Unrealized Losses			Fair Value
	(in thousands)
Current:
Certificates of deposit	$	3,667	$	—	$	—		$	3,667
United States Treasury securities		17,643		—		(16	)		17,627
	$	21,310	$	—	$	(16	)	$	21,294

Short-term investments at December 31, 2016 consist of the following:

	Cost Basis		Unrealized Gains		Unrealized Losses			Fair Value
	(in thousands)
Current:
Certificates of deposit	$	22,046	$	—	$	—		$	22,046
Agency bonds		5,917		—		(4	)		5,913
United States Treasury securities		68,766		1		(51	)		68,716
	$	96,729	$	1	$	(55	)	$	96,675

Schedule of Estimated Useful Life of Asset Classification

Depreciation and amortization is provided using the straight-line method over the estimated useful lives of the assets, which are as follows:

Asset Classification		Estimated Useful Life
Computer hardware and software		3 - 5 years
Laboratory equipment		5 years
Office equipment		5 years
Leasehold improvements		Shorter of useful life or remaining life of lease

Schedule of Computation of Basic and Diluted EPS

The following table sets forth the computation of basic and diluted EPS attributable to Inotek’s common stockholders:

	For the Years Ended December 31,
	2017			2016
	(in thousands, except share and per share amounts)
Numerator:
Net loss applicable to common stockholders	$	(29,497	)	$	(42,854	)
Denominator:
Weighted average common shares outstanding—basic and diluted		6,765,451			6,683,794
Net loss per share applicable to common stockholders—basic and diluted	$	(4.36	)	$	(6.41	)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The following common stock equivalents were excluded from the calculation of diluted net loss per share for the periods indicated as including them would have an anti-dilutive effect:

	For the Years Ended December 31,
	2017		2016
Shares issuable upon conversion of the 2021 Convertible Notes		1,620,947		1,620,947
Warrants for common stock		14,102		14,102
Stock options		523,520		668,864
Restricted Stock Units		271,719		117,500
Total		2,430,288		2,421,413

- Definition

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

+ References + Details

Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2017

Property Plant And Equipment [Abstract]

Schedule of Property and Equipment

At December 31, 2017 and 2016, Inotek’s property and equipment consisted of the following:

	December 31,
	2017			2016
	(in thousands)
Office equipment	$	357		$	407
Computer hardware and software		96			263
Laboratory equipment		—			446
Leasehold improvements		445			445
Total		898			1,561
Less: accumulated depreciation		(335	)		(431	)
Property and equipment, net	$	563		$	1,130

Accrued Expenses and Other Current Liabilities (Tables)

12 Months Ended

Dec. 31, 2017

Payables And Accruals [Abstract]

Schedule of Accrued Expenses and Other Current Liabilities

At December 31, 2017 and 2016, Inotek’s accrued expenses and other current liabilities consisted of the following:

	December 31,
	2017		2016
	(in thousands)
Compensation and benefits	$	793	$	1,627
Professional fees		528		311
Government payable		506		478
Severance and benefits		270		544
Research and development		151		1,148
Other		125		138
Total	$	2,373	$	4,246

Debt (Tables)

12 Months Ended

Dec. 31, 2017

Debt Disclosure [Abstract]

Summary of Carrying Value of Convertible Notes

The table below summarizes the carrying value of the 2021 Convertible Notes as of December 31, 2017 and 2016:

	(in thousands)
Gross proceeds	$	52,000
Initial value of issuance costs recorded as debt discount		(3,262	)
Amortization of debt discount		222
Carrying value as of December 31, 2016		48,960
Amortization of debt discount		581
Carrying value as of December 31, 2017	$	49,541

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2017

Income Tax Disclosure [Abstract]

Schedule of Net loss by Jurisdiction

Net loss by jurisdiction consists of the following:

	For the Years Ended December 31,
	2017		2016
	(in thousands)
Domestic	$	28,281	$	41,821
Foreign		1,216		1,033
Total	$	29,497	$	42,854

Schedule of Reconciliation Between Effective Tax Rates and Statutory Rates

A reconciliation between the effective tax rates and statutory rates for the years ended December 31, 2017 and 2016 is as follows:

	For the Years Ended December 31,
	2017				2016
Computed at statutory rate		34.00		%		34.00		%
State income taxes		4.34				4.76
Tax credits		1.76				3.38
Other		(6.04	)			(1.74	)
Federal rate change		(79.56	)			—
Valuation allowance		45.50				(40.40	)
		—		%		—		%

Schedule of Tax Effect of Significant Temporary Differences Representing Deferred Tax Assets and Liabilities

The tax effect of significant temporary differences representing deferred tax assets and liabilities as of December 31, 2017 and 2016 is as follows:

	December 31,
	2017			2016
	(in thousands)
Net operating loss (“NOL”) and credit carryforwards	$	37,252		$	43,765
Capitalized research and development costs		16,115			22,775
Other		1,722			1,963
Valuation allowance		(55,089	)		(68,503	)
	$	—		$	—

Schedule of Change in Unrecognized Tax Benefits

The change in unrecognized tax benefits for each of the years ended December 31, 2017 and 2016 is as follows:

	For the Years Ended December 31,
	2017			2016
	(in thousands)
Balance at January 1,	$	488		$	333
Additions for prior year tax positions		(4	)		6
Additions for current year tax positions		51			149
	$	535		$	488

Stock Plans (Tables)

12 Months Ended

Dec. 31, 2017

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Summary of Stock Option Activity

The following table summarizes the option activity for each of the years ended December 31, 2017 and 2016 under the 2014 Plan:

	Number of Shares			Weighted- Average Exercise Price Per Share		Aggregate Intrinsic Value
						(in thousands)
Outstanding as of December 31, 2015		405,190		$	19.80
Granted		289,125		$	31.08
Exercised		(21,107	)	$	18.84
Cancelled		(7,000	)	$	27.16
Outstanding as of December 31, 2016		666,208		$	24.64	$	2,064
Granted		78,750		$	7.20
Exercised		—
Cancelled		(223,062	)	$	27.04
Outstanding as of December 31, 2017		521,896		$	20.96	$	255
Vested and exercisable as of December 31, 2017		335,230		$	20.36	$	128
Weighted-average years remaining on contractual life		7.80
Unrecognized compensation cost related to non-vested stock options	$	3,459

The following table summarizes stock option activity for each of the years ended December 31, 2017 and 2016 under the 2004 Plan:

	Number of Shares			Weighted- Average Exercise Price Per Share		Aggregate Intrinsic Value
						(in thousands)
Outstanding as of December 31, 2015		2,729		$	162.32
Exercised		—		$	—
Expired		—		$	—
Cancelled		(73	)	$	162.32
Outstanding as of December 31, 2016		2,656		$	162.32
Exercised		—		$	—
Expired		(570	)	$	162.32
Cancelled		(462	)	$	162.32
Outstanding as of December 31, 2017		1,624		$	162.32	$	—
Vested and exercisable as of December 31, 2017		1,624		$	162.32	$	—
Weighted-average years remaining on contractual life		0.66
Unrecognized compensation cost related to non-vested stock options	$	—

Summary of RSU Activity

The following table summarizes the RSU activity for each of the years ended December 31, 2017 and 2016 under the 2014 Plan:

	Number of Shares			Weighted- Average Grant Date Fair Value Per Share
Outstanding as of December 31, 2015		-
Granted		117,500		$	26.00
Vested		-
Cancelled		-
Outstanding as of December 31, 2016		117,500		$	26.00
Granted		232,750		$	6.40
Vested and settled		(56,406	)	$	6.76
Cancelled		(22,125	)	$	6.80
Outstanding as of December 31, 2017		271,719		$	4.20

Schedule of Stock-Based Compensation Expense

Stock-based compensation expense for options, RSUs and the ESPP is reflected in the consolidated statements of operations as follows:

	December 31,
	2017		2016
	(in thousands)
Research and development	$	1,287	$	1,362
General and administrative		2,749		1,547
Total	$	4,036	$	2,909

Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2017

Commitments And Contingencies Disclosure [Abstract]

Schedule of Remaining Aggregate Annual Commitments Pursuant to Office Lease and Lease Amendment

As of December 31, 2017, the remaining aggregate annual commitments pursuant to the Office Lease and the Lease Amendment are as follows:

Year	(in thousands)
2018	$	411
2019		421
2020		430
2021		439
2022		445
Thereafter		74
Total	$	2,220

Fair Value of Financial Measurements (Tables)

12 Months Ended

Dec. 31, 2017

Fair Value Disclosures [Abstract]

Fair Value of Assets and Liabilities Measured on Recurring Basis

The following table sets forth Inotek’s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy:

	Fair Value Measurements at
	December 31, 2017
	Total		Level 1		Level 2		Level 3
	(in thousands)
Assets:
Money market mutual funds (included in cash and cash equivalents)	$	76,949	$	76,949	$	—	$	—

Certificates of deposit	$	3,667	$	—	$	3,667	$	—
United States Treasury securities		17,627		17,627		—		—
Short-term investments	$	21,294	$	17,627	$	3,667	$	—

	Fair Value Measurements at
	December 31, 2016
	Total		Level 1		Level 2		Level 3
	(in thousands)
Assets:
Money market mutual funds (included in cash and cash equivalents)	$	20,698	$	20,698	$	—	$	—

Certificates of deposit	$	22,046	$	—	$	22,046	$	—
Agency bonds		5,913		—		5,913		—
United States Treasury securities		68,716		68,716		—		—
Short-term investments	$	96,675	$	68,716	$	27,959	$	—

Organization and Operations - Additional Information (Detail) $ in Thousands		1 Months Ended			12 Months Ended
	Jan. 04, 2018	Aug. 31, 2016 USD ($)	Aug. 31, 2015 USD ($)	Feb. 28, 2015 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2017 USD ($)
Schedule Of Description Of Business [Line Items]
Net proceeds from issuance of common stock and convertible senior notes				$ 55,398
Proceeds from the issuance of common stock			$ 73,965
Net proceeds from second offering of convertible senior notes		$ 48,738			$ 3,997
Accumulated deficit					$ (238,877)	$ (268,374)
Aggregate cash and cash equivalents and marketable securities						$ 100,014
Subsequent Events [Member]
Schedule Of Description Of Business [Line Items]
Reverse stock split, conversion ratio	0.25
Subsequent Events [Member] \| Inotek [Member]
Schedule Of Description Of Business [Line Items]
Reverse stock split, description	1-for-4 reverse stock split
Reverse stock split, conversion ratio	0.25
Number of common stock converted for each outstanding share under merger agreement	76.185

Significant Accounting Policies - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2017 USD ($) Segment	Dec. 31, 2016 USD ($)
Summary Of Significant Accounting Policy [Line Items]
Number of operating segments \| Segment	1
Realized gains or losses on short-term investment	$ 0	$ 0
Net unrealized gains (losses) on short-term investment	38,000	(43,000)
Other than temporary impairment evaluated	$ 0	0
Tax benefits recognized likelihood of being realized upon ultimate settlement	greater than 50 percent
Accrued interest or penalties	$ 0	0
Accrued interest or penalties recognized	$ 0	0
Share based compensation forfeiture rate prior to adoption	0.00%
2021 Convertible Notes [Member] \| Level 2 [Member]
Summary Of Significant Accounting Policy [Line Items]
Short-term investments fair value disclosure	$ 38,610,000	55,640,000
2021 Convertible Notes [Member] \| Senior Notes [Member]
Summary Of Significant Accounting Policy [Line Items]
Amortization of debt issuance costs	$ 581,000	$ 222,000

Significant Accounting Policies - Schedule of Short-term Investment (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, Cost Basis	$ 21,310	$ 96,729
Available-for-sale securities, Unrealized Gains		1
Available-for-sale securities, Unrealized Losses	(16)	(55)
Available-for-sale securities, Fair Value	21,294	96,675
Certificates of Deposit [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, Cost Basis	3,667	22,046
Available-for-sale securities, Fair Value	3,667	22,046
Agency Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, Cost Basis		5,917
Available-for-sale securities, Unrealized Losses		(4)
Available-for-sale securities, Fair Value		5,913
United States Treasury Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, Cost Basis	17,643	68,766
Available-for-sale securities, Unrealized Gains		1
Available-for-sale securities, Unrealized Losses	(16)	(51)
Available-for-sale securities, Fair Value	$ 17,627	$ 68,716

Significant Accounting Policies - Schedule of Estimated Useful Lives of Asset Classification (Detail)	12 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Leasehold improvements	Shorter of useful life or remaining life of lease
Computer Hardware and Software [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Estimated Useful Life	3 years
Computer Hardware and Software [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Estimated Useful Life	5 years
Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Estimated Useful Life	5 years
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Estimated Useful Life	5 years

Significant Accounting Policies - Schedule of Computation of Basic and Diluted EPS (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Numerator:
Net loss applicable to common stockholders	$ (29,497)	$ (42,854)
Denominator:
Weighted average common shares outstanding—basic and diluted	6,765,451	6,683,794
Net loss per share applicable to common stockholders—basic and diluted	$ (4.36)	$ (6.41)

Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail) - shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	2,430,288	2,421,413
Shares Issuable Upon Conversion of the 2021 Convertible Notes [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	1,620,947	1,620,947
Warrants for Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	14,102	14,102
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	523,520	668,864
Restricted Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	271,719	117,500

Property and Equipment - Schedule of Property and Equipment (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Property and equipment, Gross	$ 898	$ 1,561
Less: accumulated depreciation	(335)	(431)
Property and equipment, net	563	1,130
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Gross	357	407
Computer Hardware and Software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Gross	96	263
Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Gross		446
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Gross	$ 445	$ 445

Property and Equipment - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Depreciation expense	$ 200	$ 169
Amount written off on fully depreciated net assets	217
Laboratory Equipment [Member] \| Research and Development [Member]
Property, Plant and Equipment [Line Items]
Impairment of assets held for sale	$ 437

Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Payables And Accruals [Abstract]
Compensation and benefits	$ 793	$ 1,627
Professional fees	528	311
Government payable	506	478
Severance and benefits	270	544
Research and development	151	1,148
Other	125	138
Total	$ 2,373	$ 4,246

Debt - 2021 Convertible Notes - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2017 USD ($) d $ / shares	Dec. 31, 2016 USD ($)	Aug. 30, 2016 USD ($)	Aug. 05, 2016 USD ($)
Debt Instrument [Line Items]
Interest expense	$ 3,579,000	$ 1,418,000
2021 Convertible Notes [Member]
Debt Instrument [Line Items]
Debt issuance costs incurred		3,262,000
2021 Convertible Notes [Member] \| Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument principal amount				$ 50,000,000
Debt instrument maturity date	Aug. 01, 2021
Debt instrument payment terms	Semi-annually
Convertible senior notes, interest rate, stated percentage	5.75%
Debt instrument payment start date	Feb. 01, 2017
Debt issuance costs incurred	$ 3,262,000
Number of shares, note gets converted into	31.1876
Principal amount	$ 1,000
Debt instrument redemption description	Inotek, at its option, may redeem for cash all or any portion of the 2021 Convertible Notes if the last reported sale price of a share of Inotek’s common stock is equal to or greater than 200% of the conversion price for the 2021 Convertible Notes then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending within the five trading days immediately preceding the date on which Inotek provides notice of redemption, at a redemption price equal to 100% of the principal amount of the 2021 Convertible Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.
Percentage of common stock conversion price	200.00%
Number of minimum trading days \| d	20
Number of consecutive trading days \| d	30
Holdings in debt outstanding	25.00%
Number of days after default	180 days
Effective interest rate	7.30%
Interest expense	$ 3,579,000	1,418,000
Amortization of debt discount	$ 581,000	$ 222,000
2021 Convertible Notes [Member] \| Senior Notes [Member] \| First 90 Days [Member]
Debt Instrument [Line Items]
Effective interest rate	0.25%
2021 Convertible Notes [Member] \| Senior Notes [Member] \| 91 to 180 Days [Member]
Debt Instrument [Line Items]
Effective interest rate	0.50%
2021 Convertible Notes [Member] \| Senior Notes [Member] \| Over-Allotment Option [Member]
Debt Instrument [Line Items]
Debt instrument principal amount			$ 2,000,000
2021 Convertible Notes [Member] \| Fundamental Change [Member]
Debt Instrument [Line Items]
Principal amount	$ 1,000
Conversion of stock, description	If the Stock Price applicable to any conversion is greater than $160.00 per share, the Conversion Rate will not be increased. If the Stock Price applicable to any conversion is less than $26.72 per share, the Conversion Rate in connection with a Make-Whole Fundamental Change Conversion will not be increased but it will be increased by 6.2375 shares in connection with a Voluntary Conversion.
Debt instrument repurchase description	Upon the occurrence of a Fundamental Change, the occurrence of certain change of control transactions or delisting events (as defined in the Indenture), each Holder may require Inotek to repurchase for cash all or any portion of the 2021 Convertible Notes held by such Holder at a repurchase price equal to 100% of the principal amount thereof, plus accrued and unpaid interest thereon.
Percentage of principal amount of notes to be purchased	100.00%
2021 Convertible Notes [Member] \| Fundamental Change [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Number of shares, note gets converted into	0
Debt Instrument, conversion rate \| $ / shares	$ 160.00
2021 Convertible Notes [Member] \| Fundamental Change [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Number of shares, note gets converted into	6.2375
Debt Instrument, conversion rate \| $ / shares	$ 26.72

Debt - Summary of Carrying Value of Convertible Notes (Detail) - 2021 Convertible Notes [Member] - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Carrying value	$ 49,541	$ 48,960
Senior Notes [Member]
Debt Instrument [Line Items]
Gross proceeds		52,000
Initial value of issuance costs recorded as debt discount		(3,262)
Amortization of debt discount	581	222
Carrying value	$ 49,541	$ 48,960

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Taxes [Line Items]
Corporate income tax rate		34.00%	34.00%
Valuation allowance, deferred tax asset, (decrease) increase		$ (13,414,000)	$ 17,312,000
Operating loss carryforwards, federal		127,132,000
Operating loss carryforwards, state		83,428,000
Unrecognized tax benefits		535,000	488,000	$ 333,000
Scenario, Forecast [Member]
Income Taxes [Line Items]
Corporate income tax rate	21.00%
Federal [Member]
Income Taxes [Line Items]
Provision for income taxes		$ 0	0
Operating loss carryforwards, expiration year		2037
Tax credit carryforwards, research and development		$ 5,171,000
State [Member]
Income Taxes [Line Items]
Provision for income taxes		$ 0	$ 0
Operating loss carryforwards, expiration year		2037
Tax credit carryforwards, research and development		$ 819,000

Income Taxes - Schedule of Net Loss by Jurisdiction (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Taxes [Line Items]
Net loss, Total	$ 29,497	$ 42,854
Domestic [Member]
Income Taxes [Line Items]
Net loss, Total	28,281	41,821
Foreign [Member]
Income Taxes [Line Items]
Net loss, Total	$ 1,216	$ 1,033

Income Taxes - Schedule of Reconciliation Between Effective Tax Rates and Statutory Rates (Detail)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Computed at statutory rate	34.00%	34.00%
State income taxes	4.34%	4.76%
Tax credits	1.76%	3.38%
Other	(6.04%)	(1.74%)
Federal rate change	(79.56%)
Valuation allowance	45.50%	(40.40%)
Effective Income Tax Rate Reconciliation,Total	0.00%	0.00%

Income Taxes - Schedule of Tax Effect of Significant Temporary Differences Representing Deferred Assets and Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Components of Deferred Tax Assets and Liabilities [Abstract]
Net operating loss (“NOL”) and credit carryforwards	$ 37,252	$ 43,765
Capitalized research and development costs	16,115	22,775
Other	1,722	1,963
Valuation allowance	(55,089)	(68,503)
Deferred Tax Assets, Net	$ 0	$ 0

Income Taxes - Schedule of Change In Unrecognized Tax Benefit (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued [Abstract]
Unrecognized Tax Benefits, Beginning Balance	$ 488	$ 333
Reduction for prior year tax positions	(4)
Additions for prior year tax positions		6
Additions for current year tax positions	51	149
Unrecognized Tax Benefits, Ending Balance	$ 535	$ 488

Equity - Additional Information (Detail)		12 Months Ended
Equity - Additional Information (Detail)	Jan. 04, 2018	Dec. 31, 2017 $ / shares shares	Dec. 31, 2016 $ / shares shares
Stockholders Equity [Line Items]
Common stock, shares authorized		120,000,000	120,000,000
Common stock, par value \| $ / shares		$ 0.01	$ 0.01
Preferred stock, shares authorized		5,000,000	5,000,000
Preferred stock, par value \| $ / shares		$ 0.001	$ 0.001
Common stock voting rights description		One vote per share
Common stock, shares outstanding		6,805,686	6,746,579
Preferred stock issued		0	0
Preferred stock outstanding		0	0
Subsequent Events [Member]
Stockholders Equity [Line Items]
Reverse stock split, conversion ratio	0.25

Stock Plans - Additional Information (Detail)	1 Months Ended					12 Months Ended
Stock Plans - Additional Information (Detail)	Oct. 31, 2017 USD ($)	Sep. 30, 2017 USD ($) Employee	Jan. 31, 2017 USD ($)	Dec. 31, 2016 USD ($) Milestone $ / shares shares	Aug. 31, 2015 USD ($)	Dec. 31, 2017 USD ($) Plan $ / shares shares	Dec. 31, 2016 USD ($) $ / shares shares	Jan. 01, 2018 shares
Stockholders Equity [Line Items]
Number of equity compensation plans \| Plan						3
Stock-based compensation expense						$ 4,036,000	$ 2,909,000
Common stock surrendered by employees for payment \| shares						3,270
Payments related to withholding taxes due						$ 16,000
Net issuance of shares excluding common stock surrendered by employees for payment \| shares						53,136
Shares vested but remained unsettled \| shares						29,375
Gross proceeds from issuance of common stock					$ 73,965,000
Common stock withheld pursuant to employee stock purchase plan						$ 35,000	155,000
Research and Development [Member]
Stockholders Equity [Line Items]
Stock-based compensation expense						1,287,000	1,362,000
General and Administrative [Member]
Stockholders Equity [Line Items]
Stock-based compensation expense						$ 2,749,000	$ 1,547,000
Accelerated Vesting of Unvested Restricted Stock Units and Stock Options [Member]
Stockholders Equity [Line Items]
Separation of employee \| Employee		10
Charge to operations		$ 158,000
Share based compensation payment award, plan modification, description and terms						Inotek also modified the employment agreements with certain of its remaining employees such that in the event of a change in control, if the employee experiences a qualifying termination by Inotek any time prior to or within 12 months of the change in control, all such employee’s outstanding stock options and RSUs will vest in full and the stock options will become exercisable. Inotek determined that the original awards were expected to vest under their original terms both prior to and after the modification
Share based compensation, incremental expense		0
Accelerated Vesting of Unvested Restricted Stock Units and Stock Options [Member] \| Research and Development [Member]
Stockholders Equity [Line Items]
Charge to operations		142,000
Accelerated Vesting of Unvested Restricted Stock Units and Stock Options [Member] \| General and Administrative [Member]
Stockholders Equity [Line Items]
Charge to operations		$ 16,000
Restricted Stock Units [Member]
Stockholders Equity [Line Items]
Vesting period			4 years
Amended and Restated 2014 Stock Option and Incentive Plan [Member]
Stockholders Equity [Line Items]
Number of shares reserved for future issuance \| shares						207,579
Percentage of outstanding common stock increased to shares available for grant						4.00%
Charge to operations	$ 856,000
Weighted-average fair value of stock option granted \| $ / shares						$ 5.72	$ 20.92
Closing price of common stock \| $ / shares				$ 24.40		$ 10.44	$ 24.40
Total options exercised \| shares							21,107
Number of shares surrendered pursuant to net exercise right \| shares							7,530
Unrecognized compensation cost related to non-vested stock options						$ 3,459,000
Stock options, intrinsic value				$ 2,064,000		255,000	$ 2,064,000
Amended and Restated 2014 Stock Option and Incentive Plan [Member] \| October 2017 Modification [Member]
Stockholders Equity [Line Items]
Unrecognized compensation cost related to non-vested stock options						$ 462,000
Amended and Restated 2014 Stock Option and Incentive Plan [Member] \| Research and Development [Member]
Stockholders Equity [Line Items]
Charge to operations	196,000
Amended and Restated 2014 Stock Option and Incentive Plan [Member] \| General and Administrative [Member]
Stockholders Equity [Line Items]
Charge to operations	$ 660,000
Amended and Restated 2014 Stock Option and Incentive Plan [Member] \| Restricted Stock Units [Member]
Stockholders Equity [Line Items]
Number of shares granted by board \| shares						232,750	117,500
Number of common stock received for contingent right \| shares				1
Stock options, terms of vesting						Vesting for these RSUs was based equally on the achievement of two performance-based conditions, subject to continued service through such achievement dates
Number of vesting achievement of performance-based conditions \| Milestone				2
Intrinsic fair value, date of grant				$ 3,055,000
Stock-based compensation expense				$ 0
Fair value of grants to be recognized due to change in vesting criteria			$ 717,000
Weighted average grant date fair value per share as of date of modification \| $ / shares						$ 4.20
Amended and Restated 2014 Stock Option and Incentive Plan [Member] \| Restricted Stock Units [Member] \| Executive Officers [Member]
Stockholders Equity [Line Items]
Number of shares granted by board \| shares				117,500
Amended and Restated 2014 Stock Option and Incentive Plan [Member] \| Subsequent Events [Member]
Stockholders Equity [Line Items]
Number of shares reserved for future issuance \| shares								272,227
2004 Stock Option Plan [Member]
Stockholders Equity [Line Items]
Stock-based compensation expense						$ 0	$ 0
Unrecognized compensation cost related to non-vested stock options						0
Stock options, intrinsic value						$ 0
Employee Stock Purchase Plan [Member]
Stockholders Equity [Line Items]
Number of shares reserved for future issuance \| shares						600,000
Percentage of outstanding common stock increased to shares available for grant						1.00%
Stock-based compensation expense						$ 6,000	66,000
Number of shares available for issuance \| shares						61,494
Percentage of minimum voting power of common stock not eligible to purchase shares						5.00%
Maximum payroll deduction of employee compensation, percentage						10.00%
Discount rate employees purchase shares on offering period						85.00%
Maximum number of shares purchased by an employee \| shares						5,000
Maximum worth of stock an employee purchases						$ 25,000
Stock purchased under ESPP \| shares						5,971
Gross proceeds from issuance of common stock						$ 35,000	155,000
Common stock withheld pursuant to employee stock purchase plan							$ 155,000
Number of shares issued \| shares							6,481
Employee Stock Purchase Plan [Member] \| Subsequent Events [Member]
Stockholders Equity [Line Items]
Number of shares reserved for future issuance \| shares								6,562

Stock Plans - Summary of Stock Option Activity (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Amended and Restated 2014 Stock Option and Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares Outstanding, Beginning Balance	666,208	405,190
Number of Shares , Granted	78,750	289,125
Number of Shares , Exercised		(21,107)
Number of Shares , Cancelled	(223,062)	(7,000)
Number of Shares Outstanding, Ending Balance	521,896	666,208
Number of Shares, Vested and exercisable	335,230
Weighted-average years remaining on contractual life	7 years 9 months 18 days
Unrecognized compensation cost related to non-vested stock options	$ 3,459,000
Weighted Average Exercise Price Per Share, Beginning Balance	$ 24.64	$ 19.80
Weighted Average Exercise Price Per Share, Granted	7.20	31.08
Weighted Average Exercise Price Per Share, Exercised		18.84
Weighted Average Exercise Price Per Share, Cancelled	27.04	27.16
Weighted Average Exercise Price Per Share, Ending Balance	20.96	$ 24.64
Weighted Average Exercise Price Per Share, Vested and exercisable	$ 20.36
Aggregate Intrinsic Value, Outstanding Beginning Balance	$ 2,064,000
Aggregate Intrinsic Value, Outstanding Ending Balance	255,000	$ 2,064,000
Aggregate Intrinsic Value, Vested and exercisable	$ 128,000
2004 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares Outstanding, Beginning Balance	2,656	2,729
Number of Shares, Expired	(570)
Number of Shares , Cancelled	(462)	(73)
Number of Shares Outstanding, Ending Balance	1,624	2,656
Number of Shares, Vested and exercisable	1,624
Weighted-average years remaining on contractual life	7 months 28 days
Unrecognized compensation cost related to non-vested stock options	$ 0
Weighted Average Exercise Price Per Share, Beginning Balance	$ 162.32	$ 162.32
Weighted Average Exercise Price Per Share, Expired	162.32
Weighted Average Exercise Price Per Share, Cancelled	162.32	162.32
Weighted Average Exercise Price Per Share, Ending Balance	$ 162.32	$ 162.32
Aggregate Intrinsic Value, Outstanding Ending Balance	$ 0
Weighted Average Exercise Price Per Share, Vested and exercisable	$ 162.32

Stock Plans - Summary of RSU Activity (Detail) - Restricted Stock Units [Member] - Amended and Restated 2014 Stock Option and Incentive Plan [Member] - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding, Beginning Balance	117,500
Number of Shares, Granted	232,750	117,500
Number of Shares, Vested and settled	(56,406)
Number of Shares, Cancelled	(22,125)
Number of Shares, Outstanding, Ending Balance	271,719	117,500
Weighted Average Grant Date Fair Value Per Share, Beginning Balance	$ 26.00
Weighted Average Grant Date Fair Value Per Share, Granted	6.40	$ 26.00
Weighted Average Grant Date Fair Value Per Share, Vested and settled	6.76
Weighted Average Grant Date Fair Value Per Share, Cancelled	6.80
Weighted Average Grant Date Fair Value Per Share, Ending Balance	$ 4.20	$ 26.00

Stock Plans - Schedule of Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 4,036	$ 2,909
Research and Development [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	1,287	1,362
General and Administrative [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 2,749	$ 1,547

Commitments and Contingencies - Additional Information (Detail) $ in Thousands	1 Months Ended	12 Months Ended
	Sep. 30, 2017 USD ($) Employee	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)
Operating Leased Assets [Line Items]
Commencement date of lease				2015-09
Acquisition of leasehold improvements				$ 445
Lease amendment commencement date			Jul. 01, 2016
Lease term			90 months
Lease extension term			5 years
Lease description			The lease term is 90 months and Inotek has the right to extend the term for one period of five years.
Operating leases, rent expenses		$ 337	$ 275
Fees owe to advisor upon change in control		$ 528	311
Merger agreement consummation Date		Jan. 04, 2018
Research and development expense		$ 14,193	31,985
Stock options expected to vest during period		$ 4,036	2,909
Transition Agreement [Member]
Operating Leased Assets [Line Items]
Description of Transition Agreement		Pursuant to the terms of the Transition Agreement, Dr. McVicar remained an employee of the Company as a Senior Advisor for a six-month period ending April 4, 2017 (the “Transition Period”) and for twelve months thereafter will receive his salary and medical benefits at the same rate in effect as of the date of the Transition Agreement.
Former Chief Scientific Officer [Member] \| Transition Agreement [Member]
Operating Leased Assets [Line Items]
Research and development expense			862
Payments to former employee on termination		$ 591
Bonus paid to former employee on his termination		102
Accrued severance		$ 106
Former Chief Scientific Officer [Member] \| Transition Agreement [Member] \| Stock Options [Member]
Operating Leased Assets [Line Items]
Stock options expected to vest during period			$ 215
Whitehead v. Inotek Pharmaceuticals Corporation [Member] \| Pending Litigation [Member]
Operating Leased Assets [Line Items]
Lawsuit filing date		January 6, 2017
Amended complaint filing date		July 10, 2017
Second amended complaint filing date		September 5, 2017
Name of plaintiff		purported stockholder of Inotek
Lawsuit action domicile		U.S. District Court for the District of Massachusetts
Name of defendant		David Southwell, and Rudolf Baumgartner
Lawsuit allegation, description		The second amended complaint alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5 against the Company, David Southwell, and Rudolf Baumgartner based on allegedly false and misleading statements and omissions regarding Inotek’s phase 2 and phase 3 clinical trials of trabodenoson.
Lawsuit management action, description		The lawsuit seeks, among other things, unspecified compensatory damages for purchasers of Inotek’s common stock between July 23, 2015 and July 10, 2017, as well as interest and attorneys’ fees and costs. The defendants filed a motion to dismiss the second amended complaint on October 6, 2017, the plaintiffs opposed the motion on December 5, 2017, and the defendants filed a reply on January 16, 2018. Inotek continues to vigorously defend itself against this claim.
Plaintiffs opposed motion date		Dec. 05, 2017
Defendants filed a reply date		Jan. 16, 2018
Change-in-Control Benefits [Member]
Operating Leased Assets [Line Items]
Employment termination benefits, description		In September 2017, Inotek modified the employment agreements with certain of its remaining employees such that in the event of termination in connection with a change in control (“CIC”), Inotek will provide these employees severance payments at each employee’s current monthly salary rate, and continued medical, dental and vision coverage pursuant to COBRA (of the employer’s portion of the premium cost) for up to six months primarily depending on duration of each individual employee’s service. Inotek also modified the employment agreements with certain of its named executive officers. In the event of a qualifying termination in connection with a CIC, for each of Inotek’s Chief Medical Officer and Vice President, Finance, Inotek will pay (i) twelve and six months’ severance, respectively, at each person’s current monthly salary rate, and (ii) continued medical, dental and vision coverage pursuant to COBRA (of the employer’s portion of the premium cost), for twelve and six months, respectively. In the event of a qualifying termination in connection with a CIC, in addition to the severance benefits previously provided to Inotek’s Chief Executive Officer (consisting of a lump-sum payment equal to 18 months’ base salary), Inotek agreed to provide continued medical, dental and vision coverage pursuant to COBRA (of the employer’s portion of the premium cost), for eighteen months.
Number of remaining employees eligible for retention bonus \| Employee	7
Retention bonus payable in aggregate	$ 642
Change-in-Control Benefits [Member] \| Perella Weinberg Partners, LP [Member] \| Merger of Rome Merger Sub with and into Rocket Pharmaceuticals, Ltd [Member]
Operating Leased Assets [Line Items]
Fees owe to advisor upon change in control	$ 2,000

Commitments and Contingencies - Schedule of Remaining Aggregate Annual Commitments Pursuant to Office Lease and Lease Amendment (Detail) $ in Thousands	Dec. 31, 2017 USD ($)
Commitments And Contingencies Disclosure [Abstract]
2018	$ 411
2019	421
2020	430
2021	439
2022	445
Thereafter	74
Total	$ 2,220

Fair Value of Financial Measurements - Fair Value of Assets and Liabilities Measured on Recurring Basis (Detail) - Fair Value Measurements, Recurring [Member] - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Money Market Mutual Funds [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Money market mutual funds (included in cash and cash equivalents)	$ 76,949	$ 20,698
Money Market Mutual Funds [Member] \| Level 1 [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Money market mutual funds (included in cash and cash equivalents)	76,949	20,698
Certificates of Deposit [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Short-term investments fair value disclosure	3,667	22,046
Certificates of Deposit [Member] \| Level 2 [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Short-term investments fair value disclosure	3,667	22,046
Agency Bonds [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Short-term investments fair value disclosure		5,913
Agency Bonds [Member] \| Level 2 [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Short-term investments fair value disclosure		5,913
United States Treasury Securities [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Short-term investments fair value disclosure	17,627	68,716
United States Treasury Securities [Member] \| Level 1 [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Short-term investments fair value disclosure	17,627	68,716
Short-term Investments [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Short-term investments fair value disclosure	21,294	96,675
Short-term Investments [Member] \| Level 1 [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Short-term investments fair value disclosure	17,627	68,716
Short-term Investments [Member] \| Level 2 [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Short-term investments fair value disclosure	$ 3,667	$ 27,959

Benefit Plans - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Compensation Related Costs [Abstract]
Contribution to savings plan	$ 154	$ 168
Savings plan termination date	Jan. 03, 2018

Subsequent Events - Additional Information (Detail) $ / shares in Units, $ in Thousands				1 Months Ended	12 Months Ended
	Jan. 26, 2018 USD ($)	Jan. 24, 2018 $ / shares shares	Jan. 04, 2018	Aug. 31, 2015 USD ($)	Dec. 31, 2016 shares
Subsequent Event [Line Items]
Proceeds from the issuance of common stock \| $				$ 73,965
Common Stock [Member]
Subsequent Event [Line Items]
Shares issued					120,672
Subsequent Events [Member]
Subsequent Event [Line Items]
Reverse stock split, conversion ratio			0.25
Subsequent Events [Member] \| Common Stock [Member] \| Underwriting Agreement [Member]
Subsequent Event [Line Items]
Shares price per share \| $ / shares		$ 13.25
Proceeds from the issuance of common stock \| $	$ 78,778,000
Subsequent Events [Member] \| Common Stock [Member] \| Underwriters [Member] \| Underwriting Agreement [Member]
Subsequent Event [Line Items]
Number of shares granted to purchase		825,000
Shares price per share \| $ / shares		$ 12.455
Subsequent Events [Member] \| Maximum [Member] \| Common Stock [Member] \| Underwriting Agreement [Member]
Subsequent Event [Line Items]
Shares issued		6,325,000
Subsequent Events [Member] \| Inotek [Member]
Subsequent Event [Line Items]
Date of reverse merger			Jan. 04, 2018
Reverse stock split, description			1-for-4 reverse stock split
Reverse stock split, conversion ratio			0.25
Number of common stock converted for each outstanding share under merger agreement			76.185
Merger agreement, description			As a result of the reverse stock split, the per share exercise price of, and the number of shares of common stock underlying, Inotek’s stock options and warrants outstanding prior to the reverse stock split were automatically proportionally adjusted based on the 4-to-1 reverse stock split ratio in accordance with the terms of such options and warrants. The reverse stock split did not alter the par value of Inotek’s common stock or modify any voting rights or other terms of the common stock.
Subsequent Events [Member] \| Inotek [Member] \| Private Rocket [Member]
Subsequent Event [Line Items]
Number of common stock converted for each outstanding share under merger agreement			76.185